Elizabeth Gaughan

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16

Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti–PD-1 Therapies in Metastatic Melanoma

Douglas B. Johnson, Jennifer Bordeaux, Ju Young Kim et al. · Clinical Cancer Research · 2018 · 176 citations

Life Sciences, Immunology, Oncology +17

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

Marit M. Melssen, Gina R. Petroni, Kimberly A. Chianese‐Bullock et al. · Journal for ImmunoTherapy of Cancer · 2019 · 99 citations · Full text

Medicine, Immunology, Oncology +17

Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature

Joshua E. Reuss, Paul R. Kunk, Anne M. Stowman et al. · Journal for ImmunoTherapy of Cancer · 2016 · 96 citations · Full text

Medicine, Immunology, Oncology +17